Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kliment

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Neoplasma|January 27, 2010
Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancerM Tajtakova, A Pidanicova, L Valansky, et al.
The Journal of Urology|October 19, 1999
Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group TrialT M de Reijke, F I Keuppens, P Whelan, et al.
Ceskoslovenska Farmacie|June 1, 1990
[Clinical evaluation of a new radiopharmaceutical agent 99mTc-mercaptoacetyltriglycine (MAG3)]J Lepej, P Altmann, A Marosová, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancerR P Abratt, D Brune, M-A Dimopoulos, et al.
European Urology|April 15, 2000
Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893S D Fosså, D Curran, N K Aaronson, et al.
The New England Journal of Medicine|July 19, 2013
Alpha emitter radium-223 and survival in metastatic prostate cancerC Parker, S Nilsson, D Heinrich, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Neoplasma|January 27, 2010
Serum level of IGFBP3 and IGF1/IGFBP3 molar ratio in addition to PSA and single nucleotide polymorphism in PSA and CYP17 gene may contribute to early diagnostics of prostate cancerM Tajtakova, A Pidanicova, L Valansky, et al.
The Journal of Urology|October 19, 1999
Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group TrialT M de Reijke, F I Keuppens, P Whelan, et al.
Ceskoslovenska Farmacie|June 1, 1990
[Clinical evaluation of a new radiopharmaceutical agent 99mTc-mercaptoacetyltriglycine (MAG3)]J Lepej, P Altmann, A Marosová, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancerR P Abratt, D Brune, M-A Dimopoulos, et al.
European Urology|April 15, 2000
Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893S D Fosså, D Curran, N K Aaronson, et al.
The New England Journal of Medicine|July 19, 2013
Alpha emitter radium-223 and survival in metastatic prostate cancerC Parker, S Nilsson, D Heinrich, et al.
Pageof 5